Anilú Margarita Saucedo-Sariñana

Dr. Anilú Margarita Saucedo-Sariñana


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
ASAnilú Margarita Saucedo-Sariñana
Anilú Margarita Saucedo-Sariñana
CLCarlos Roberto Lugo-Escalante
Carlos Roberto Lugo-Escalante
PBPatricio Barros-Núñez
Patricio Barros-Núñez
MMMaría Eugenia Marín-Contreras
María Eugenia Marín-Contreras
TPTomas Daniel Pineda-Razo
Tomas Daniel Pineda-Razo
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
Colorectal cancer (CRC) is the third most common cancer in the world. Overall survival is related to clinical stage: more advanced stages show lower survival rates; therefore, they need to be monitored regularly with new, less invasive and more specific biomarkers. The concentration and integrity index of circulating cell-free DNA (ccfDNA) have been proposed as potential diagnostic and prognostic biomarkers for CRC, however, inconsistent results are still observed in different reports. Here we analyze these potential CRC biomarkers in a Mexican population. In this study, 124 patients with sporadic CRC and 37 healthy individuals were examined as a reference group. The ccfDNA was isolated from plasma samples of all included subjects. The ccfDNA concentration was determined by fluorometry and the integrity index (ALU247/ALU115 ratio) by quantitative PCR amplification (qPCR) of ALU sequences. The results show that ccfDNA concentration was higher in CRC patients than in the reference group (P=0.001). The integrity index showed no significant differences between these groups (P=0.258), except for histological type (P=0.012). A higher ccfDNA concentration was also associated with patients younger than 50 years (P=0.030). The ccfDNA concentration showed significant discriminatory power (AUC: 0.854, C.I.: 0.78-0.92, P=0.001) between patients and the reference group and between tumor-node-metastasis (TNM) stages. In conclusion, ccfDNA concentration proves to be a good diagnostic biomarker for CRC patients, whereas the integrity index did not show diagnostic utility.

8 September 2025 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
JRJessica Fabiola Rodriguez-Ortiz
Jessica Fabiola Rodriguez-Ortiz
ASAnilú Margarita Saucedo-Sariñana
Anilú Margarita Saucedo-Sariñana
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
JPJanet Soto Padilla
Janet Soto Padilla
RORocio Ortiz-Lopez
Rocio Ortiz-Lopez
PBPatricio Barros-Núñez
Patricio Barros-Núñez
The objective of this study was to evaluate the concentration and integrity index of circulating cell-free DNA (ccf-DNA) as biomarkers for the detection and monitoring of minimal residual disease (MRD) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Comparison with a validated methodology for the quantification of monoclonal rearrangements of the IGH gene was made. Peripheral blood and bone marrow samples were collected from 10 pediatric patients with B-ALL at diagnosis, remission, and maintenance phases. Total ccf-DNA concentration was estimated using Qubit® fluorometry, and the integrity index was obtained through qPCR amplification of ALU247/ALU115 fragments. Monoclonal rearrangements of the IGH gene were quantified by multiplex PCR and detected by capillary electrophoresis. Results showed that at diagnosis, the mean ccf-DNA concentration was 5,607 ng/mL with an integrity index of 0.38; during remission induction, they were 968 ng/mL and 0.35; and during the maintenance phase, 748 ng/mL and 0.33, respectively. Differences between treatment phases were significant (p=0.02). The reference group had a mean ccf-DNA concentration of 247 ng/mL and an integrity index of 0.20, showing significant differences compared to the patient group (p=0.01). Monoclonality analysis showed significant differences between diagnosis and remission (p=0.022) and between diagnosis and maintenance (p=0.001). Linear regression analysis during treatment demonstrated a similar trend for ccf-DNA concentration and monoclonality. In conclusion, ccf-DNA concentration and integrity index could be useful biomarkers for monitoring MRD in patients with B-ALL, showing comparable efficacy to the detection of monoclonality in the IGH gene.

27 November 2024 in Cellular and Molecular Biology
Verified
Journal Article
Open access
ASAnilú Margarita Saucedo-Sariñana
Anilú Margarita Saucedo-Sariñana
YTYuri Giovanna Vanessa Trujillo-Fernández
Yuri Giovanna Vanessa Trujillo-Fernández
CJClara Ibet Juárez-Vázquez
Clara Ibet Juárez-Vázquez
MGMiriam Yadira Godínez-Rodríguez
Miriam Yadira Godínez-Rodríguez
CJCesar de Jesus Tovar Jacome
Cesar de Jesus Tovar Jacome
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
Connective tissue growth factor (CTGF) and Caspase 8 (CASP8) have been implicated in cancer development and progression. Variants such as CASP8 rs3834129 (-652 6N I/D) and CTGF rs6918698 (-945 C>G) have been associated with several cancers, although their association is still debated between populations. This study investigates the possible association between the CASP8 rs3834129 and CTGF rs6918698 variants with colorectal cancer (CRC) in Mexican patients. Genomic DNA was extracted from 250 CRC patients and 250 control subjects. The identification of CASP8 and CTGF variants was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. The association was determined by the odds ratio (OR) analysis and P values were adjusted by the Bonferroni correction. Patients carrying the D/D genotype for the CASP8 rs3834129 variant exhibited an increased susceptibility to CRC (P = 0.012). The D/D genotype was associated with older 50-year-old patients (P = 0.006). In addition, this same D/D genotype was associated with TNM II stage (P = 0.013) and rectal localization (P = 0.023). Additionally, patients carrying the G/G genotype for the CTGF rs6918698 variant showed a decreased susceptibility to CRC (P = 0.009), and in the sex stratification, this gene has protective role in males (P = 0.008). This same genotype was associated with decreased susceptibility to early TNM stages (I+II) (P = 0.023) and right-sided colon tumor localization (P = 0.002). There was no association between response to treatment and the variants analyzed. Our findings suggest that the CASP8 rs3834129 and CTGF rs6918698 variants have a significant impact on the development of CRC.

4 June 2026 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
ASAnilú Margarita Saucedo-Sariñana
Anilú Margarita Saucedo-Sariñana
CJClara Juarez
Clara Juarez
CJCesar de Jesus Tovar Jacome
Cesar de Jesus Tovar Jacome
RSRubria Alicia González Sánchez
Rubria Alicia González Sánchez
Martha GallegosMartha Gallegos
Martha Gallegos
Recent evidence has highlighted the crucial role of non-coding genetic elements in regulating gene expression and has been linked to a broad range of biological functions. Notably, dysregulation of long non-coding RNAs has been strongly associated with tumorigenesis and cancer progression. Background/Objectives: This study aimed to investigate the potential association between the H19 rs3741219 T>C, MEG3 rs7158663 G>A, POLR2E rs3787016 T>C, and ANRIL rs10757274 A>G variants and Breast Cancer (BC) susceptibility, as well as their relationship with clinicopathological characteristics in Mexican patients. Methods: DNA was obtained from peripheral blood samples of 505 women (254 patients and 251 control females). Genotyping was performed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) methodology. Associations were calculated using odds ratios (ORs), with p-values adjusted by the Bonferroni test (p < 0.012). In silico analyses were conducted to predict the functional impact of the variants associated. Results: Patients carrying the C/C genotypes in H19 rs3741219 and POLR2E rs3787016 variants showed increased susceptibility to developing BC and with clinical and pathological characteristics (age at diagnosis, TNM stage, histologic type and molecular subtype) (p < 0.001). Conclusions: The results suggest that H19 rs3741219 and POLR2E rs3787016 variants significantly influence BC risk.

Verified
Journal Article
Open access
PDF file
AOAlejandra Berenice Ochoa-Hernández
Alejandra Berenice Ochoa-Hernández
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
Luis Felipe Jave-SuárezLuis Felipe Jave-Suárez
Luis Felipe Jave-Suárez
Adriana Aguilar-LemarroyAdriana Aguilar-Lemarroy
Adriana Aguilar-Lemarroy
Jesús García-GómezJesús García-Gómez
Jesús García-Gómez
PBPatricio Barros-Núñez
Patricio Barros-Núñez
Background: The absence of Fragile X Mental Retardation Protein (FMRP) causes Fragile-X syndrome (FXS), the most frequent form of inherited intellectual disability. Recent evidence suggests that individuals with FXS have a decreased risk of developing cancer, and overexpression of FMRP has been linked to cancer progression. The aim of the present study is to examine the expression of multiple Wnt/β-catenin pathway components in FXS patients. Methods: Fifteen molecularly confirmed FMR1 full-mutation males and 15 age-matched male controls were studied. Total RNA from peripheral blood mononuclear cells (PBMCs) was used to quantify the expression of 15 Wnt/β-catenin pathway genes by real-time PCR (qPCR), and Western blot analysis was performed to assess β-catenin protein in nuclear and cytoplasmic PBMC fractions. Results: WNT7A, PPP2R5C, FOSL1, and JUN showed significantly reduced expression in FXS patients versus controls. Western blot consistently detected a ~60–65 kDa immunoreactive band, rather than full-length β-catenin, in cytoplasmic fractions of both groups, with nuclear presence in a subset of patients. Conclusions: These findings suggest dysregulation of the Wnt/β-catenin signaling pathway in FXS patients and identify a potentially novel molecular alteration in β-catenin that deserves further investigation.